692 related articles for article (PubMed ID: 24164459)
21. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
22. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
[TBL] [Abstract][Full Text] [Related]
23. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
Ichikawa J; Ishii H; Bonaccorso S; Fowler WL; O'Laughlin IA; Meltzer HY
J Neurochem; 2001 Mar; 76(5):1521-31. PubMed ID: 11238736
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
25. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism.
Chung YC; Li Z; Dai J; Meltzer HY; Ichikawa J
Brain Res; 2004 Oct; 1023(1):54-63. PubMed ID: 15364019
[TBL] [Abstract][Full Text] [Related]
26. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex.
Ichikawa J; Dai J; Meltzer HY
Brain Res; 2002 Jun; 939(1-2):34-42. PubMed ID: 12020849
[TBL] [Abstract][Full Text] [Related]
27. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study.
Shearman E; Rossi S; Szasz B; Juranyi Z; Fallon S; Pomara N; Sershen H; Lajtha A
Brain Res Bull; 2006 Mar; 69(2):204-13. PubMed ID: 16533671
[TBL] [Abstract][Full Text] [Related]
28. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.
Ichikawa J; Meltzer HY
Brain Res; 2000 Mar; 858(2):252-63. PubMed ID: 10708676
[TBL] [Abstract][Full Text] [Related]
29. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
30. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner.
Liégeois JF; Ichikawa J; Meltzer HY
Brain Res; 2002 Aug; 947(2):157-65. PubMed ID: 12176156
[TBL] [Abstract][Full Text] [Related]
31. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
32. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
[TBL] [Abstract][Full Text] [Related]
33. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.
Kuroki T; Meltzer HY; Ichikawa J
J Pharmacol Exp Ther; 1999 Feb; 288(2):774-81. PubMed ID: 9918588
[TBL] [Abstract][Full Text] [Related]
34. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
35. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
[TBL] [Abstract][Full Text] [Related]
36. Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.
Horiguchi M; Huang M; Meltzer HY
Psychopharmacology (Berl); 2011 Sep; 217(1):13-24. PubMed ID: 21432027
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
[TBL] [Abstract][Full Text] [Related]
38. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
[TBL] [Abstract][Full Text] [Related]
39. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex.
Huang M; Li Z; Ichikawa J; Dai J; Meltzer HY
Brain Res; 2006 Jul; 1099(1):44-55. PubMed ID: 16824491
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.
Li Z; Ichikawa J; Meltzer HY
Psychopharmacology (Berl); 2003 May; 167(3):315-23. PubMed ID: 12664192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
